Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px
Document › Details

Cobo Technologies ApS. (4/15/19). "News: Cobo Technologies Member of NIST Genome Editing Consortium, US".

Region Region United States (USA)
Organisations Organisation Cobo Technologies ApS
  Group Cobo Technologies (Group)
  Organisation 2 NIST Genome Editing Consortium
  Group United States (govt)
Products Product genome editing (gene editing)
  Product 2 CRISPR INDEL Profiling Platform (CIPP™)
Index term Index term United States (govt)–Cobo Technologies: genome editing, 201904– collab Cobo beomes member of NIST Genome Editing Consortium
Person Person Herlevsen, Hasse (Cobo Technologies 201904– COO + Co-Owner before Leo Pharma)
     


We are excited to announce that we have become member of the NIST - Genome Editing Consortium in US.

Our team will contribute with our broad knowledge about INDEL analysis of CRISPR modified cells using our proprietary INDEL Profiling Platform, CIPP - powered by the IDAA method.

Read also the announcement in the Danish MEDWATCH 2019-04-16

Learn more about the NIST - Genome Editing Consortium below or at the webpage:

"Targeted genome editing, a method used to alter the DNA of living cells at desired locations, is poised to revolutionize science and medicine. To fight diseases, novel genome edited therapeutics, including those for use in regenerative medicine and infectious diseases, are being developed. Many commercial applications including agriculture and chemical production, are also leveraging this technology. Whether genome editing will be used in healthcare, agriculture or basic research, robust quantitative measurements are needed to enable high confidence characterization of DNA alterations. NIST has brought together experts across the genome editing field including stakeholders in industry, academia and government to assess their measurement needs. These discussions have identified common pre-competitive measurements and standards needed to establish greater confidence in the characterization of genome editing outputs. The NIST- Genome Editing Consortium has been established to address these needs"

Goals:

Evaluate genome editing assay pipelines
Develop benchmark materials
Generate benchmark data
Develop suggested minimal information reporting for public studies
Generate a common lexicon for genome editing studies

https://medwatch.dk/secure/Top_picks_in_english/article11323389.ece

https://www.nist.gov/programs-projects/nist-genome-editing-consortium

   
Record changed: 2023-06-05

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Cobo Technologies (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px




» top